How to Start a Peptide Business That Can Take Payments

To start a peptide business that can actually take payments, you build four things in order. A legal entity with a bank account in the same name. A research-use storefront that agrees with itself. A document file built around certificates of analysis. And a merchant account underwritten for what you sell. Most guides to starting a peptide business list that last step as “specialized high-risk payment processing” and stop. This page is that step, and it starts earlier than founders expect, because a risk team reads the other three before it reads your application.

Key takeaways

• Starting a peptide business has four build steps, and the payment account is the one every guide names and none explain. Apply for it before launch, not after a mainstream platform closes you.
• Processing statements are a shortcut for pricing risk, not a requirement. With none, the review shifts onto your store, your paperwork, and your projections.
• Your website is the largest single input. A reviewer reads it the way a customer would, and dosing language undoes a research-use disclaimer sitting three clicks away.
• The network programs that punish disputes need volume you do not have yet, but a terminated-merchant listing does not. Mastercard’s excessive-chargeback listing has no minimum chargeback count, and listings last 5 years (Stripe, 2026).
• The 2026 federal peptide news is about compounding pharmacies, not online research-supply stores. It will not help your application, and citing it can hurt.

How do you start a peptide business?

In the order a reviewer will read it, not the order most founders build it.

1. Form the entity and open the bank account first. Incorporate, get an EIN, and open a business bank account in the company’s legal name. The name on your storefront, the name on the bank account and the name on your merchant application should be the same name. Underwriting matches all three, and a mismatch is a question you would rather not have to answer in your first week.
2. Build the storefront as a research-use store from the first page. Age-gating at entry, a research-use acknowledgment at checkout, and product pages with no dosing, injection, or outcome language. Do this before launch rather than cleaning it up later, because a reviewer reads the live site as it stands on the day you apply.
3. Assemble the document file before you take an order. Current certificates of analysis matched to the compounds and lots on your site, supplier invoices, and published refund and shipping policies. What a certificate of analysis does and does not do for your application is covered in certificates of analysis and merchant accounts.
4. Apply for the merchant account before you launch, not after. A mainstream signup is a light automated screen, and the real review often arrives months later, once volume exists. Applying to a provider that underwrites the category up front means the account you launch on is the account you keep. Our peptide merchant accounts page covers what that review involves.
5. Write down the numbers you will be asked for. Projected monthly volume, average order value, refund policy, shipping times, and how you handle a customer who wants money back. These are the questions on the application, and the next sections cover what a startup can put in place of the processing history it does not have.

Whether the compounds may lawfully be sold the way you plan to sell them is your counsel’s question, and no payment application answers it. What this page covers is the payment side, which is the step most first-time sellers get to last and should get to first.

Can a peptide startup get approved with no statements?

Yes, and the reason is worth understanding, because it tells you what to build.

Statements are the fastest way for a risk team to price you. Three months of processing history shows real sales, real refunds, real disputes, and real customer behavior. Nothing you write on an application competes with that. So when a provider asks for statements, it is asking for the cheapest reliable evidence, not the only acceptable evidence.

A startup has to supply that evidence a different way. You are asking a reviewer to underwrite a plan instead of a track record, which means the plan has to be specific, documented, and consistent with what your site actually says.

One thing not to read as evidence is a mainstream signup. Getting switched on by a large platform is a light automated screen, not a verdict on your category, and the real look often comes months later. That gap is the subject of why processors decline peptide sellers.

It also helps to know how few processors ban this category outright in writing. Of the eight processors whose published policies we track, Wise names “anabolic steroids and peptides” as prohibited. Adyen names peptides and research chemicals in two places, restricted for business-to-business sales and prohibited when you sell direct to consumers, which is what an online store does. Stripe’s nearest entry covers “incorrectly labeled research chemicals,” which turns on your labeling. Square’s published list of banned activities does not mention peptides at all, and Square still terminated a peptide seller in August 2026. You can read the verbatim text for each one in our prohibited businesses lookup.

What underwriting reads when there is no history

With no statements in the file, a reviewer works through six things. All six are visible to you today.

• Your storefront. This is the big one. A reviewer opens your site and reads it as a buyer would. Dosing charts, injection instructions, before-and-after photos, and results claims all say the product is meant for people, whatever your footer says.
• Your catalog. Research peptides sit near categories most risk teams already decline. A catalog that also carries SARMs gets underwritten on the SARMs, because the FDA treats those as unapproved new drugs and has said that selling them as dietary supplements to work around review is illegal.
• Your documentation. Certificates of analysis, supplier records, and a clear research-use acknowledgment at checkout give a reviewer something to weigh in your favor. Without them there is nothing on your side of the scale.
• Your corporate file. Incorporation documents, an EIN, a business bank account in the company’s name, and clear ownership details. On a new company the owner’s own background carries more weight than it would otherwise.
• Your money plan. Projected monthly volume, average order value, refund policy, shipping times, and how you handle a customer who wants money back. These numbers are how the account gets sized.
• Your customer-facing basics. A billing descriptor customers will recognize, a working support address, and a phone number that someone answers. Disputes start when a buyer cannot reach you.

What you can put in place of processing history

Every item below is a substitute for the evidence you do not have. None of them is exotic, and a first-time seller can assemble all of them in a week.

• A consistent store. Age-gating at entry, a research-use acknowledgment at checkout, and product pages with no dosing, injection, or outcome language. Consistency is what makes any single signal count.
• Certificates of analysis for what you actually sell. Current ones, matched to the compounds and lot numbers on your site, not a generic PDF from a supplier’s marketing page.
• Supplier invoices and a sourcing story. Where the product comes from, who tested it, and what happens to a batch that fails.
• Published policies. Refunds, shipping windows, and returns, written plainly and posted where a customer sees them before paying. These are dispute prevention, and a reviewer knows it.
• A realistic projection. State the monthly volume and average order value you actually expect in your first quarter. An inflated number is the fastest way to invite scrutiny you did not need.
• Prior history from elsewhere. If you or a partner ran a different company through a merchant account, those statements are still useful. They show how you handled refunds and disputes, even for another business.
• Money in the bank. A funded business account and some working capital matter more here than on an established file, because a new account often carries a reserve while it builds a record.

Expect terms that reflect the missing history. A new high-risk account commonly starts with a volume cap and a rolling reserve, and both usually loosen as the record fills in. That is not a penalty. It is the shape of pricing risk without data.

The first-month numbers a new seller should know

Here is the part that surprises founders. The famous card-network programs need more volume than you have, but the listing that follows a termination does not.

Visa’s monitoring program flags an account at what it calls the excessive level at a 1.5% ratio with at least 1,500 disputes and fraud events in a month in the US, and it publishes a lower non-compliant tier at a 0.5% ratio with a count of 5 (Stripe, 2026). Mastercard’s excessive-chargeback program starts at 100 to 299 chargebacks a month at a 1.5% to 2.99% rate. On 300 orders a month, the big thresholds are far away, and the lower Visa tier is not.

The terminated-merchant databases are the real exposure. Acquirers have to screen every applicant against Mastercard’s MATCH and Visa’s VMSS before approval, and they have to report a merchant they terminate. Mastercard’s excessive-chargeback reason code triggers when a month’s chargebacks pass 1% of that month’s Mastercard sales and total $5,000 or more, and there is no minimum chargeback count. Stripe’s own worked example is a merchant with 125 transactions and 6 chargebacks worth $6,250, which qualifies. Listings last 5 years (Stripe, 2026).

Read that twice if you are launching. A single bad month at small volume can put your company and your name in a database that every future acquirer checks, and winning those disputes later does not remove the entry. If you are already in that position, our MATCH and TMF page covers what is still available to you.

Where research-use-only labeling fits, and where it does not

Research-use-only labeling is worth having, and it is not a legal safe harbor. Under federal rules, what a product is intended for is judged from the whole offer, including your advertising, your statements, and the circumstances of how you sell. A disclaimer under a dosing chart does not outweigh the dosing chart.

Payment reviewers apply the same logic and reach the answer faster, because they are reading your site rather than briefing a case. What the labeling posture changes is whether your file can be reviewed at all. A store that agrees with itself can be underwritten. A store that contradicts itself gets declined without much explanation. We go through the detail in what research-use-only labeling does for a merchant account.

What the 2026 federal news does not change for a new seller

Two 2026 developments come up constantly in this category, and neither one helps your application.

On April 15, 2026 the FDA announced it would remove 12 peptides from Category 2 of its compounding bulk-substances list, effective about a week later, because the people who nominated them withdrew the nominations (Orrick, 2026). Category 2 is where the agency puts substances it has identified significant safety risks for. Removal takes off that label. It does not add anything to the approved list, and it does not make a substance permitted.

Then on July 23 and 24, 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding six peptides to the 503A list, including BPC-157, TB-500 and Semax, and voted against a seventh. That committee advises. Its votes are not binding on the FDA, and formal rulemaking still has to happen before a compounding pharmacy has clear authority to prepare them (NCPA, 2026). A further committee review of more peptides is scheduled before the end of February 2027.

All of it concerns licensed pharmacies compounding for patients with prescriptions. That is a different business from selling research compounds online. Putting it in an application as evidence that your category is clearing up will read as a misunderstanding of your own regulatory position, which is not the impression a new file needs. This page prices payment risk, not legality, and the legal questions belong to your own counsel.

How fast can a new peptide business start taking payments?

Two different clocks run here, and mixing them up is how founders get sold something they did not want.

The bank-debit rail, called e-debit or ACH, pulls funds from a customer’s bank account rather than running a card. It boards the same day with next-day funding, which is why plenty of new sellers turn it on first and add cards once those are reviewed. Card acceptance runs on real underwriting, and a well-prepared file moves faster than a thin one. Our instant approval page lays out both halves honestly.

Treat any advertisement pairing “guaranteed” with approval as a red flag. For a category like this one, a guarantee means either the account is not really being underwritten, which sets up a freeze once volume starts, or the promise disappears the moment you apply.

What to have ready before you apply

Get the store right first, because it is the document a reviewer reads whether or not you send it. Pull the dosing language. Move the research-use acknowledgment to checkout. Put your certificates of analysis somewhere a person can find them. Write the refund policy you intend to honor.

Then assemble the corporate file, the supplier records, and a projection you would defend out loud. When you are ready, start your application and we will go through your vertical, your documents, and the realistic timeline for your file. Our peptide merchant accounts page covers what that review involves before you get on a call.